Posters

Traditional antidepressant monotherapies are associated with poor outcomes in patients with impaired symptom domains of anhedonia and interest-activity. AXS-05 (dextromethorphan-bupropion; AUVELITY) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved in the US for treatment of major depressive disorder (MDD) in adults.

This study examined whether an online CME clinical demonstration module can improve learners’ self-reported clinical behaviors related to management of MDD, identifying patients who may benefit from pharmacogenomic testing (PGx), interpreting the results and incorporating data into clinical decision-making, communicating benefits and limitations of PGx to patients.

Anhedonia is a core symptom of major depressive disorder (MDD). However, there is a lack of understanding of the healthcare and humanistic burden associated with prominent anhedonia in patients with MDD.

The Pathway Platform was designed to enhance patient-provider engagement and encourage use of outcome measures for major depressive disorder (MDD) to improve adherence to measurement-based care (MBC) in primary care. This post hoc subgroup analysis of the Pathway Platform implementation study examined the effect of antidepressant (AD) changes on outcomes.

Anhedonia is a key symptom of Major Depressive Disorder (MDD), however, there is limited knowledge about the impact of prominent anhedonia on clinical improvement and treatment satisfaction in patients diagnosed with MDD.